Trinity Biotech plc announced a strategic collaboration with medical artificial intelligence (?AI?) company PulseAI to enhance the Company?s recently acquired continuous glucose monitor (CGM) biosensor technology. Under this collaboration, Trinity Biotech will provide a pool of unique multi-parameter CGM datasets from Trinity Biotech?s existing biosensor database to PulseAI. This data will be used to support the design and implementation of Trinity Biotech?s AI-driven health & wellness analytics platform.

This platform will be a key component of Trinity Biotech?s CGM solution, further differentiating the affordable, needle-free and reusable diabetes management solution that Trinity plans to launch across global markets. PulseAI are experts in evidence-based medical AI and have extensive experience in scaling AI algorithm training using medical sensor datasets. PulseAI have worked in association with Mayo Clinic to train their machine learning algorithms using large-scale datasets captured across millions of patients.